Theravance Biopharma to present new YUPELRI analyses at CHEST 2025 meeting.

A retrospective cohort study of claims data showed that patients adherent to YUPELRI experienced fewer and less severe exacerbations and had lower healthcare costs than non-adherent patients. Post-hoc analyses of a Phase 3 safety study demonstrated that patients taking YUPELRI had lower incidence of moderate-to-severe acute exacerbations and overall less severe exacerbations than those taking tiotropium.

Theravance Biopharma, Inc. (NASDAQ: TBPH) has announced that it will be presenting new analyses on YUPELRI (revefenacin) at the upcoming CHEST 2025 annual meeting of the American College of Chest Physicians. The presentations will highlight the effectiveness of YUPELRI in reducing exacerbations and healthcare costs in patients with chronic obstructive pulmonary disease (COPD).

The first presentation, titled "Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety Study," will be delivered by Edmund J Moran, Ph.D. The study, conducted by Theravance Biopharma, found that patients taking YUPELRI had significantly lower incidence of moderate-to-severe acute exacerbations and overall less severe exacerbations compared to those taking tiotropium over a 52-week period Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting^[1].

The second presentation, titled "Adherence to Revefenacin Associated with Reductions in Exacerbations and Healthcare Costs Following a COPD-Related Hospitalization," will be presented by Grace Leung, MPH, of Zavicus Consulting. This retrospective cohort study of claims data demonstrated that adherent patients to YUPELRI experienced significantly fewer and less severe exacerbations, and had significantly lower healthcare costs than non-adherent patients in the 3 months following hospital discharge Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting^[1].

These presentations underscore the potential of YUPELRI as a once-daily nebulized maintenance treatment for COPD patients. The findings provide compelling evidence supporting the use of YUPELRI and its dual benefit on patient outcomes, both in terms of reducing exacerbations and lowering healthcare costs.

The presentations will take place on October 21, 2025, at the CHEST 2025 annual meeting in Chicago, IL. For more information, visit www.theravance.com.